Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Recent clinical trial update news from Aethlon Medical, Inc. ( Nasdaq: AEMD ), Envoy Medical, Inc. ( Nasdaq: COCH ), ...

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...

Northside Hospital is leading the way to bringing advanced cancer immunotherapies, like Tumor Infiltrating Lymphocyte (TIL) ...

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration.

Prof David Kerr discusses a recent study investigating tumor mutational burden as a potential contributing factor to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. The acquisition will add OTX-201, an investigational ...

said James (Jim) Frakes, CEO and CFO of Aethlon Medical. In the initial three patients, there were encouraging changes in ...

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...